Charles Schwab
ARIA

Charles Schwab’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Charles Schwab’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-778,437
Closed -$9.68M – 3094
2016
Q4 		$9.68M Buy
778,437
+47,033
+6% +$566K 0.01% 1280
2016
Q3 		$10M Buy
731,404
+57,074
+8% +$573K 0.01% 1163
2016
Q2 		$4.98M Buy
674,330
+115,774
+21% +$869K 0.01% 1559
2016
Q1 		$3.57M Sell
558,556
-20,835
-4% -$117K ﹤0.01% 1723
2015
Q4 		$3.62M Buy
579,391
+1,555
+0.3% +$10.2K ﹤0.01% 1730
2015
Q3 		$3.38M Buy
577,836
+37,445
+7% +$288K 0.01% 1742
2015
Q2 		$4.47M Buy
540,391
+16,846
+3% +$149K 0.01% 1617
2015
Q1 		$4.32M Buy
523,545
+25,008
+5% +$185K 0.01% 1604
2014
Q4 		$3.42M Buy
498,537
+17,853
+4% +$112K 0.01% 1702
2014
Q3 		$2.6M Sell
480,684
-70,635
-13% -$413K ﹤0.01% 1816
2014
Q2 		$3.51M Buy
551,319
+246,780
+81% +$1.7M 0.01% 1650
2014
Q1 		$2.46M Sell
304,539
-22,508
-7% -$175K ﹤0.01% 1839
2013
Q4 		$2.23M Buy
327,047
+30,165
+10% +$163K ﹤0.01% 1851
2013
Q3 		$5.61M Buy
296,882
+31,782
+12% +$617K 0.01% 1078
2013
Q2 		$5.18M Buy
+265,100
New +$4.7M 0.01% 1018

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Charles Schwab's ARIA Position: Q1 2017 in Review

Charles Schwab sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 778,437 shares — an estimated $9.68M sold.

Charles Schwab first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $10M in Q3 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Charles Schwab reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Charles Schwab sold 778,437 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $9.68M.
  • Charles Schwab first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Charles Schwab's Ariad Pharmaceuticals Inc position peaked at $10M in Q3 2016.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Charles Schwab's 13F filing for Q1 2017, filed 15 May 2017.